Salvatore G - Search Results

1

BAY 43-9006 inhibition of oncogenic RET mutants.

Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M. Carlomagno F, et al. Among authors: salvatore g. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. doi: 10.1093/jnci/djj069. J Natl Cancer Inst. 2006. PMID: 16507829

2

BRAF is a therapeutic target in aggressive thyroid carcinoma.

Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M. Salvatore G, et al. Clin Cancer Res. 2006 Mar 1;12(5):1623-9. doi: 10.1158/1078-0432.CCR-05-2378. Clin Cancer Res. 2006. PMID: 16533790 Free article.

3

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.

Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M. Nappi TC, et al. Among authors: salvatore g. Cancer Res. 2009 Mar 1;69(5):1916-23. doi: 10.1158/0008-5472.CAN-08-1693. Epub 2009 Feb 17. Cancer Res. 2009. PMID: 19223553

4

Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.

Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M. Salvatore G, et al. J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80. doi: 10.1210/jc.2003-032221. J Clin Endocrinol Metab. 2004. PMID: 15472223

5

Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.

Salvatore G, Chiappetta G, Nikiforov YE, Decaussin-Petrucci M, Fusco A, Carney JA, Santoro M. Salvatore G, et al. Eur J Cancer. 2005 Mar;41(5):816-21. doi: 10.1016/j.ejca.2005.01.004. Eur J Cancer. 2005. PMID: 15763659

6

Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.

Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M. Guida T, et al. Among authors: salvatore g. J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9. doi: 10.1210/jc.2004-2459. Epub 2005 May 17. J Clin Endocrinol Metab. 2005. PMID: 15899946

7

Receptor tyrosine kinase inhibitors in thyroid cancer.

Castellone MD, Carlomagno F, Salvatore G, Santoro M. Castellone MD, et al. Among authors: salvatore g. Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1023-38. doi: 10.1016/j.beem.2008.09.012. Best Pract Res Clin Endocrinol Metab. 2008. PMID: 19041829 Review.

8

Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.

Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, Fenzi G, Vecchio G, Fusco A, Santoro M. Salvatore D, et al. Among authors: salvatore g. J Clin Endocrinol Metab. 2000 Oct;85(10):3898-907. doi: 10.1210/jcem.85.10.6882. J Clin Endocrinol Metab. 2000. PMID: 11061555

9

The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.

Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M. Carlomagno F, et al. Among authors: salvatore g. Cancer Res. 1997 Feb 1;57(3):391-5. Cancer Res. 1997. PMID: 9012462

10

Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.

Cirafici AM, Salvatore G, De Vita G, Carlomagno F, Dathan NA, Visconti R, Melillo RM, Fusco A, Santoro M. Cirafici AM, et al. Among authors: salvatore g. Endocrinology. 1997 Apr;138(4):1450-5. doi: 10.1210/endo.138.4.5073. Endocrinology. 1997. PMID: 9075701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

382 results

Search Page